Want to receive this post in your inbox every day? Sign up for the Supply Lines newsletter, and follow Bloomberg Economics on Twitter for more.
Three years ago, manufacturing gadgets in China was a given. That’s changed fundamentally in the era of trade wars and coronavirus.
Under the new reality, the world’s electronics makers are actively seeking ways to diversify their supply chains and reduce their dependence on any single country, no matter how attractive.
This Is How Your Immune System Reacts to #Coronavirus: https://bit.ly/3bHkdnv by Dana G Smith Explaining why COVID-19 induces different symptoms on different individuals. #COVID19 #CoronavirusOutbreak
Here’s how the immune system responds when a person catches Covid-19 — and what that means for treatment.
The coronavirus can travel up to 23–27 feet :
This JAMA Insights Clinical Update discusses the need to better understand the dynamics of respiratory disease transmission by better characterizing transmission routes, the role of patient physiology in shaping them, and best approaches for source control in the context of the COVID-19 outbreak.
The Guardian reported that Brown would have liked the U.N. Security Council to have been invited to an emergency online meeting of the G20 countries today. The meeting, hosted by Saudi Arabia, is tackling the issue of the novel coronavirus.
“This is not something that can be dealt with in one country,” Brown said.
“There has to be a coordinated global response.”
As research on Alzheimer’s disease (AD) advances, a desperate need remains for an easy blood test to help diagnose the condition as early as possible. Ideally, such a test could also distinguish AD from other forms of dementia that produce similar symptoms. As published recently in Nature Medicine, an NIH-funded research team has designed a simple blood test that is on course to meet these criteria [1].
The latest work builds on a large body of work showing that one secret to predicting a person’s cognitive decline and treatment response in AD lies in a protein called tau. Using the powerful, but expensive, approach of PET scan imaging, we know that tau builds up in the brain as Alzheimer’s disease progresses. We also know that some tau spills from the brain into the bloodstream.
The trouble is that the circulating tau protein breaks down far too quickly for a blood test to offer a reliable measure of what’s happening in a person’s brain. A few years ago, researchers discovered a possible solution: test for blood levels of a slightly different and more stable version of the protein called pTau181 [2]. (The “p” in its name comes from the addition of phosphorus in a particular part of the protein’s structure.)
The 19 3D-printable parts that make up the mask are visible on the Maker Mask website along with details on materials needed, download instructions, videos, the ability to donate to the cause and more. The cost of each finished mask, printed in about three hours, is estimated to be between $2 and $3.
A technology veteran and a 3D-printing “savant” have teamed with other members of industry, health care and government to launch Maker Mask, a Seattle nonprofit creating medically endorsed, reusable protective masks using everyday 3D printers.
Jonathan Roberts, founder and partner at the Bellevue, Wash.-based venture capital firm Ignition Partners, is also a co-founder of RPrime, a nonprofit that is helping to fund the mask-making initiative. The former Microsoft executive said the goal is to address critical supply shortages and support “the real heroes on the front lines” of the COVID-19 pandemic.
The respirator-style mask with a replaceable HEPA filter and other commonly available parts, was developed by Rory Larson, a rapid prototyping expert with 10 years experience in engineering, CAD, 3D printing, CNC and small batch production manufacturing. It took just a week for the group, working with Larson’s design, to get a small production facility up and running out of Epiphany Parish in Seattle.
Cancer is one of humanity’s leading killers, and the main reason for that is it’s often hard to detect until it’s too late. But that might be about to change. Researchers have developed a new type of AI-powered blood test that can accurately detect over 50 different types of cancer and even identify where it is in the body.
There are just so many types of cancer that it’s virtually impossible to keep an eye out for all of them through routine tests. Instead, the disease usually isn’t detected until doctors begin specifically looking for it, after a patient experiences symptoms. And in many cases, by then it can be too late.
Ideally, there would be a routine test patients can undergo that would flag any type of cancer that may be budding in the body, giving treatment the best shot of being successful. And that’s just what the new study is working towards.
** On Saturday Dr. Vladimir Zelenko reported that he has now successfully treated 699 COVID-19 patients in New York for the coronavirus. Dr. Zelenko reported 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.
** On Friday night the French research team led by the renowned epidemiologist Dr. Didier Raoult was able to repeat his findings from a previous study. Dr. Raoult administered hydroxychloroquine and azithromycin to 80 patients and observed improvement in EVERY CASE except for a very sick 86-year-old with an advanced form of coronavirus infection.
On Sunday night the FDA issued an emergency authorization for hydroxychloroquine to be prescribed to coronavirus patients.
The newly emergent human virus SARS-CoV-2 is resulting in high fatality rates and incapacitated health systems. Preventing further transmission is a priority. We analyzed key parameters of epidemic spread to estimate the contribution of different transmission routes and determine requirements for case isolation and contact-tracing needed to stop the epidemic. We conclude that viral spread is too fast to be contained by manual contact tracing, but could be controlled if this process was faster, more efficient and happened at scale. A contact-tracing App which builds a memory of proximity contacts and immediately notifies contacts of positive cases can achieve epidemic control if used by enough people. By targeting recommendations to only those at risk, epidemics could be contained without need for mass quarantines (‘lock-downs’) that are harmful to society. We discuss the ethical requirements for an intervention of this kind.
COVID-19 is a rapidly spreading infectious disease caused by the novel coronavirus SARS-COV-2, a betacoronavirus, which has now established a global pandemic. Around half of infected individuals become reported cases, and with intensive care support, the case fatality rate is approximately 2%. More concerning is that the proportion of cases requiring intensive care support is 5%, and patient management is complicated by requirements to use personal protective equipment and engage in complex decontamination procedures. Fatality rates are likely to be higher in populations older than in Hubei province (such as in Europe), and in low-income settings where critical care facilities are lacking. In the public health cost of failing to achieve sustained epidemic suppression was estimated as 250,000 lives lost in the next few months in Great Britain, and 1.1−1.2 million in the USA, even with the strongest possible mitigation action to ‘flatten the curve’.